<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
FORM 8-K
----------------------
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) JANUARY 10, 2000
ALEXION PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 0-27756 13-3648318
- ---------------------------- ----------- -------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
25 SCIENCE PARK, NEW HAVEN, CT 06511
- ---------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (203) 776-1790
NOT APPLICABLE
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
ITEM 5. OTHER EVENTS
On January 10, 2000, Alexion Pharmaceuticals, Inc. issued the press
release filed herewith as Exhibit 99.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) EXHIBITS.
99 Press Release dated January 10, 2000.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ALEXION PHARMACEUTICALS, INC.
Date: January 10, 2000 By: /s/ LEONARD BELL
------------------------------------------
Name: Leonard Bell, M.D.
Title: President, Chief Executive Officer,
Secretary and Treasurer
<PAGE>
EXHIBIT INDEX
99 Press Release, dated January 10, 2000.
<PAGE>
Exhibit 99
IMMEDIATE RELEASE:
Contacts:
David Keiser Patricia F. Dimond, Ph.D. Burns McClellan,
Executive VP and COO Director of Corporate Inc.
Alexion Pharmaceuticals, Development and Ethan Denkensohn
(203) 776-1790 Genzyme Transgenics (Investors)
Corporation Miriam Weber
(508) 270-2374 (Media)
(212) 213-0006
Genzyme Transgenics Corporation and ALEXION Pharmaceuticals
Inc. Sign Agreement for Transgenic Collaboration
FRAMINGHAM, Mass. and NEW HAVEN, Conn., Jan. 10 -- Genzyme Transgenics
Corporation (Nasdaq: GZTC - news) and Alexion Pharmaceuticals, Inc. (Nasdaq:
ALXN - news) announced today that they have signed an agreement to produce a
recombinant protein using GTC's transgenic manufacturing system. Under this
agreement, Genzyme Transgenics will work with Alexion to develop a large scale
manufacturing approach for one of Alexion's recombinant protein products.
"Our alliance with Alexion affirms the value of transgenic production in the
development and potential commercialization of protein therapeutics," said
Sandra Nusinoff Lehrman, M.D., President and Chief Executive Officer of Genzyme
Transgenics. "We are pleased to initiate this relationship with Alexion, a
partner who shares our commitment to provide innovative new therapies for unmet
medical needs."
In the first phase of this program, Genzyme Transgenics will develop transgenic
animals that produce the recombinant protein in their milk, for which Genzyme
Transgenics will receive development and milestone fees from Alexion. Depending
on results of the development and clinical programs, it is expected that the
companies would enter into supply agreements for clinical and commercial
production.
"In concert with the expanded breadth of our development programs, we are
pleased to be working with Genzyme Transgenics on this project," said David
Keiser, Executive Vice President and Chief Operating Officer for Alexion. "We
look forward to gaining important benefits that this technology can offer for
high volume, low cost protein production."
<PAGE>
Genzyme Transgenics Corporation has successfully produced over 60 human proteins
in animals' milk, including monoclonal antibodies, immunoglobulin fusion
proteins, hard-to-express and plasma proteins, achieving higher expression and
at greater volume than can be obtained using alternate production systems.
Genzyme Transgenics is currently working with recognized leaders in the
biotechnology and pharmaceutical industries, like Alexion Pharmaceuticals, to
produce transgenic proteins as potential treatments for a variety of diseases,
such as autoimmune and inflammatory disorders, cardiovascular diseases, and
HIV/AIDS.
Genzyme Transgenics Corporation applies transgenic technology to enable the
development and production of recombinant proteins and monoclonal antibodies for
medical uses. Primedica Corporation, Genzyme Transgenics' contract research
organization, provides preclinical development and testing services to
pharmaceutical, biotechnology, medical device and other companies. Genzyme
Transgenics Corporation is also developing idiotypic vaccines in collaboration
with the National Cancer Institute.
Alexion is engaged in the development of products for the treatment of
cardiovascular, autoimmune and neurologic diseases caused by undesired effects
of the human immune system. Alexion's two lead product candidates are currently
in six clinical development programs- 5G1.1-SC, in a Phase IIb cardiopulmonary
bypass efficacy trial and two Phase II myocardial infarction efficacy trials in
collaboration with Procter & Gamble; and 5G1.1, in Phase II efficacy trials for
the chronic treatment of rheumatoid arthritis and membranous nephritis.
This press release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Such forward-looking statements are
subject to a number of risks, uncertainties and other factors that could cause
actual results to differ materially from future results expressed or implied by
such statements. Factors that may cause such differences include, but are not
limited to, those discussed in Genzyme Transgenics Corporation's prospectuses
and Forms 10-K and Alexion's prospectuses and Forms 10-K, as filed with the
Securities and Exchange Commission, including the uncertainties associated with
product development, the risk that clinical trials will not commence when
planned, the risks that a product will not prove to be safe and effective and
uncertainties associated with dependence upon the actions of government and
regulatory agencies, including, without limitation, the risk that such
regulators will not grant the requisite approval for a product on a timely basis
or at all.
